+ Site Statistics
+ Search Articles
+ Subscribe to Site Feeds
Most Shared
PDF Full Text
+ PDF Full Text
Request PDF Full Text
+ Follow Us
Follow on Facebook
Follow on Twitter
Follow on LinkedIn
+ Translate
+ Recently Requested

Role of the EZH2 histone methyltransferase as a therapeutic target in cancer

Role of the EZH2 histone methyltransferase as a therapeutic target in cancer

Pharmacology and Therapeutics 165: 26-31

Besides being a genetic disease, cancer is also an epigenetic disease. The histone methyltransferase EZH2 is the catalytic subunit of PRC2, a highly conserved protein complex that regulates gene expression by methylating lysine 27 on histone H3. Given its role in tumorigenesis and its prognostic value in several tumor types, this protein appears a relevant therapeutic target. This review focuses on the preclinical and preliminary clinical results of studies investigating EZH2 inhibitors in human malignancies. These emerging data suggest that EZH2 inhibitors represent a very promising class of drugs, which will probably have a major impact on improving outcome and reducing toxicity for patients with indolent and aggressive B-cell lymphomas and other specific solid tumors.

(PDF emailed within 0-6 h: $19.90)

Accession: 058791039

Download citation: RISBibTeXText

PMID: 27179746

DOI: 10.1016/j.pharmthera.2016.05.003

Related references

Histone Methyltransferase EZH2: A Therapeutic Target for Ovarian Cancer. Molecular Cancer Therapeutics 17(3): 591-602, 2018

Validation of the histone methyltransferase EZH2 as a therapeutic target for various types of human cancer and as a prognostic marker. Cancer Science 102(7): 1298-1305, 2011

The histone methyltransferase EZH2 is a therapeutic target in small cell carcinoma of the ovary, hypercalcaemic type. Journal of Pathology 242(3): 371-383, 2017

The histone methyltransferase EZH2 as a druggable target in SHH medulloblastoma cancer stem cells. Oncotarget 8(40): 68557-68570, 2017

Triptolide inhibits histone methyltransferase EZH2 and modulates the expression of its target genes in prostate cancer cells. Asian Pacific Journal of Cancer Prevention 14(10): 5663-5669, 2015

Oncogenic histone methyltransferase EZH2: A novel prognostic marker with therapeutic potential in endometrial cancer. Oncotarget 8(25): 40402-40411, 2017

Epigenetic regulation of signaling pathways in cancer: role of the histone methyltransferase EZH2. Journal of Gastroenterology and Hepatology 26(1): 19-27, 2011

EZH2 Histone Methyltransferase and JMJD3 Histone Demethylase Implications in Prostate Cancer. Omics 21(12): 751-753, 2017

The JMJD3 Histone Demethylase and the EZH2 Histone Methyltransferase in Prostate Cancer. Omics 20(2): 123-125, 2016

The histone methyltransferase G9a: a new therapeutic target in biliary tract cancer. Human Pathology 72: 117-126, 2017

Histone demethylase KDM2B upregulates histone methyltransferase EZH2 expression and contributes to the progression of ovarian cancer in vitro and in vivo. Oncotargets and Therapy 10: 3131-3144, 2017

The histone methyltransferase G9a as a therapeutic target to override gemcitabine resistance in pancreatic cancer. Oncotarget 7(38): 61136-61151, 2016

The role of histone methyltransferase EZH2 in myelodysplastic syndromes. Expert Review of Hematology 5(2): 177-185, 2012

Roles of the EZH2 histone methyltransferase in cancer epigenetics. Mutation Research 647(1-2): 21-29, 2008

Targeting histone methyltransferase EZH2 as cancer treatment. Journal of Biochemistry 156(5): 249-257, 2015